Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
11,749
datasets available to search
ShareScore release 0.9.0
Dataset results
11,749 results for “patient safety”
A Safety and Efficacy Study in Patients With Gastric Cancer
ClinicalTrials.gov study NCT00400179. IPD Sharing: Not stated. Countries: 2. Publications: 2.
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Des
ClinicalTrials.gov study NCT01292473. IPD Sharing: Not stated. Countries: 8. Publications: 8.
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
ClinicalTrials.gov study NCT00927472. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients
ClinicalTrials.gov study NCT01016912. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
ClinicalTrials.gov study NCT05502081. IPD Sharing: YES. Countries: 1. Publications: 10.
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor
ClinicalTrials.gov study NCT01350804. IPD Sharing: Not stated. Countries: 15. Publications: 2.
The effectiveness and safety of intensive lipid-lowering with different Rosuvastatin-based regimens in patients at high risk: A nonblind, randomized, controlled trial
Open the record for dataset details and reuse information.
Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis
Open the record for dataset details and reuse information.
Factors related to the implementation of patient safety culture in prehospital emergency services
Open the record for dataset details and reuse information.
Data from: An exploratory study of staff perceptions of shift safety in the critical care unit and routinely available data on workforce, patient and organisational factors
<p><b>Objectives </b></p> <p>To explore: bedside professional reported (BPR) perceptions of safety in intensive care staff; and the relationships between BPR safety, staffing, patient and work environment characteristics.</p> <p><b>Design </b>An exploratory study of self-recorded staff perceptions of shift safety and routinely collected data.</p> <p><b>Setting </b>A large teaching hospital comprising 70 critical care beds.</p> <p><b>Participants </b>All clinical staff working in adult critical care.</p> <p><b>Interventions </b>Staff recorded whether their shift felt "safe, unsafe or very unsafe" for 29 consecutive days. We explored these perceptions and relationships between these and routine data on staffing, patient and environmental characteristics.</p> <p><b>Outcome measures</b> Relationships between BPR safety and staffing, patient and work environment characteristics.</p> <p><b>Results</b> 2836 BPR scores were recorded over 29 consecutive days (response rate 57.7%). Perceptions of safety varied between staff, including within the same shift. There was no correlation between perceptions of safety and two measures of staffing; care hours per patient day (r= 0.13 p=0.108) and Safecare Allocate (r= -0.19 p=0.013). We found a significant, positive relationship between perceptions of safety and the percentage of Level 3 (most severely ill) patients (r=0.32, p=0.0001). There was a significant inverse relationship between perceptions of safety and the percentage of Level 1 patients on a shift (r= -0.42, p=<0.0001). Perceptions of safety correlated negatively with increased numbers of patients (r= -0.44, p=0.0006) and higher percentage of patients located side rooms (r=0.63, p<0.0001). We found a significant relationship between perceptions of safety and the percentage of staff with a specialist critical care course (r=0.42. p=0.0001).</p> <p><b>Conclusion </b>Existing staffing models, which are primarily influenced by staff:patient ratios may not be sensitive to patient need. Other factors may be important drivers of staff perceptions of safety and should be explored further.</p> <p><b>Trial registration</b>- UK Health Research Authority approval was obtained (ID249248).</p>
Comparison of Clinical Efficacy and Safety of Amnio-Graft Versus Skin Graft in Injury Patients: Retrospective Cohort Study
<p>Al Mujtahid Hospital, Damascus, Syria</p><p><strong>Title of the Study</strong>: Comparison of Clinical Efficacy and Safety of Amnio-Graft versus Skin Graft in Plastic Surgery</p><p><strong>Principal Investigator</strong>: Dr. Wael Barazi, President of the Plastic Surgery Department</p><p><strong>Study Duration</strong>: From February 19, 2023, to October 23, 2023</p><p>I. <strong>Background and Rationale</strong>:</p><p>Plastic surgery, a rapidly evolving field, continuously explores novel techniques to enhance patient outcomes. This retrospective cohort study aims to compare the clinical efficacy and safety of amnio-graft and skin graft procedures performed in the Plastic Surgery Department of Al Mujtahid Hospital in Damascus, Syria.</p><p>II.<strong> Objectives</strong>:</p><p>To assess the clinical efficacy of amnio-graft and skin graft procedures.</p><p>To evaluate the safety profile of amnio-graft and skin graft procedures.</p><p>To compare the outcomes of patients undergoing plastic surgery with amnio-graft versus skin graft.</p><p>III. <strong>Study Design</strong>:</p><p>This study will adopt a retrospective cohort design, analyzing data collected from patient records in the Plastic Surgery Department during the specified study duration.</p><p>IV. Participants:</p><p>The study will include all patients who underwent either amnio-graft or skin graft procedures within the defined study period.</p><p>V. <strong>Data Collection</strong>:</p><p>Primary Data:</p><p>Patient demographics</p><p>Preoperative clinical characteristics</p><p>Surgical details</p><p>Postoperative outcomes</p><p>Adverse events</p><p>Secondary Data:</p><p>Histopathological findings</p><p>Follow-up information</p><p>Hospitalization duration</p><p>Any additional relevant clinical information</p><p>VI. <strong>Data Analysis</strong>:</p><p>Statistical analysis will be conducted to compare clinical outcomes and safety profiles between the amnio-graft and skin graft groups. Descriptive statistics, such as mean, median, and standard deviation, will be used, and inferential statistics, including chi-square tests and t-tests, will be applied where appropriate.</p><p>VII. <strong>Ethical Considerations:</strong></p><p>Patient Confidentiality:</p><p>All patient information will be kept confidential, with data anonymized during analysis.</p><p><strong>Informed Consent:</strong></p><p>As this is a retrospective study, no new interventions will be performed. Informed consent will not be obtained.</p><p><strong>Patient Welfare:</strong></p><p>Patient welfare and safety are paramount. The study design aims to minimize risks associated with data collection.</p><p><strong>VIII. Potential Risks and Benefits:</strong></p><p><strong>Risks</strong>:</p><p>There are no additional risks associated with this retrospective study as it involves the analysis of existing medical records.</p><p><strong>Benefits</strong>:</p><p>The study results may contribute to improved decision-making in plastic surgery procedures, enhancing patient outcomes.</p><p><strong>IX. Approval</strong>:</p><p>This research protocol has been reviewed and approved by the Institutional Review Board (IRB) of Al Mujtahid Hospital.</p><p>IRB Approval Date: [27/11/2023]</p><p>IRB Approval Code: [<strong>63211</strong>]</p><p><i>Note: Any amendments to this protocol will require additional review and approval by the Institutional Review Board.</i></p><p> </p>
Safety and efficacy of remote ischemic postconditioning after thrombolysis in patients with stroke
<p><span><b>Objective: </b>To determine the effect of remote ischemic post-conditioning (RIPC) on acute ischemic stroke (AIS) patients undergoing intravenous thrombolysis (IVT).</span></p> <p><span><b>Methods: </b>A single-center, randomized controlled trial was performed with AIS patients receiving IVT. Patients in the RIPC group were administered RIPC treatment (after IVT) during hospitalization. The primary endpoint was a score of 0 or 1 on the modified Rankin scale (mRS) at day 90. The safety, tolerability and neuroprotection biomarkers associated with RIPC were also examined.</span></p> <p><span><b>Results: </b>We collected data from both RIPC (n=34) and controls (n=34). The average duration of hospitalization was 11.2 days. There was no significant difference between the two groups at admission for the NIHSS score (p=0.364) or occur to treatment time (p=0.889). An excellent recovery (mRS 0–1) at 3 months was obtained in 71.9% of the patients in the RIPC group vs 50.0% in the control group (adjusted risk ratio, 9.85; 95% CI, 1.54 to 63.16; P = 0.016). We further found significantly lower plasma S100 β (p=0.007) and higher vascular endothelial growth factor (p = 0.003) levels in the RIPC group than in controls.</span></p> <p><span><b>Conclusions: </b>Repeated RIPC combined with IVT can significantly facilitate recovery of nerve function and improve clinical prognosis of patients with AIS.</span></p>
Analysis of the effectiveness and safety of conventional anticoagulants in preventing deep vein thrombosis after total knee arthroplasty in patients undergoing total knee arthroplasty at high altitudes
<p><strong><span>Analysis of the effectiveness and safety of conventional anticoagulants in preventing deep vein thrombosis after total knee arthroplasty in patients undergoing total knee arthroplasty at high altitudes</span></strong></p>
Assessment of Patient Safety Culture and Associated Factors among Healthcare Professionals in Public Hospitals of Bahir Dar City, Northwest Ethiopia: A Mixed-Methods Study
<p><span>This dataset contains raw data of "Socio-Demographic and Socio-Economic, and organizational and work related characteristics" on the assessment of patient safety culture among healthcare professionals in public hospitals of Bahir Dar City, Northwest Ethiopia.</span></p>
Comparative Efficacy and Safety of Sitagliptin Phosphate Combined with Gliclazide Sustained-Release Tablets Versus Metformin in Treatment-Naïve Patients with Type 2 Diabetes Mellitus and Glucotoxicity: A Single-Center, Prospective, Randomized Controlled Non-Inferiority Study
<p>This dataset supports the manuscript titled "Comparative Efficacy and Safety of Sitagliptin Phosphate Combined with Gliclazide Sustained-Release Tablets Versus Metformin in Treatment-Naïve Patients with Type 2 Diabetes Mellitus and Glucotoxicity: A Single-Center, Prospective, Randomized Controlled Non-Inferiority Study." The study aims to compare the efficacy and safety of sitagliptin phosphate combined with gliclazide sustained-release tablets against metformin in treatment-naïve patients with type 2 diabetes mellitus and glucotoxicity. Data include clinical measurements, laboratory test results, and adverse event records collected throughout the trial period. Statistical analyses were conducted to assess non-inferiority between the two treatment groups. This dataset provides valuable insights for researchers interested in diabetes management, pharmacotherapy, and randomized controlled trials.</p>
Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis
<p><b>Objective</b>: To report safety of ocrelizumab (OCR) up to 7 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) enrolled in clinical trials or treated in real-world postmarketing settings.</p> <p><b>Methods</b>: Safety analyses are based on integrated clinical and laboratory data for all patients who received OCR in 11 clinical trials, including the controlled treatment and open-label extension (OLE) periods of the phase 2 and 3 trials, plus the phase 3b trials VELOCE, CHORDS, CASTING, OBOE, ENSEMBLE, CONSONANCE, and LIBERTO. For selected adverse events (AEs), additional postmarketing data were used. Incidence rates of serious infections and malignancies were contextualized using multiple epidemiologic sources.</p> <p><b>Results</b>: At data cut-off (January 2020), 5,680 patients with multiple sclerosis (MS) received OCR (18,218 patient years [PY] of exposure) in clinical trials. Rates per 100 PY (95% CI) of AEs (248; 246–251), serious AEs (7.3; 7.0–7.7), infusion-related reactions (25.9; 25.1–26.6), and infections (76.2; 74.9–77.4) were similar to those within the controlled treatment period of the phase 3 trials. Rates of the most common serious AEs, including serious infections (2.01; 1.81–2.23) and malignancies (0.46; 0.37–0.57), were consistent with the ranges reported in epidemiologic data.</p> <p><b>Conclusion</b>: Continuous administration of OCR for up to 7 years in clinical trials, as well as its broader use for more than 3 years in the real-world setting, are associated with a favorable and manageable safety profile, without emerging safety concerns in a heterogeneous MS population.</p> <p><b>Classification of Evidence</b>: This analysis provides Class III evidence that long-term, continuous treatment with OCR has a consistent and favorable safety profile in patients with RMS and PPMS. This study is rated Class III because of the use of OLE data and historical controls.</p>
Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage
ClinicalTrials.gov study NCT01787123. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
ClinicalTrials.gov study NCT01756339. IPD Sharing: Not stated. Countries: 17. Publications: 1.
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
ClinicalTrials.gov study NCT02794857. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Safety and Efficacy of Ga68-IAC PET/CT for Diagnosis and Clinical Management in Metastatic Breast Cancer Patients
ClinicalTrials.gov study NCT04480619. IPD Sharing: YES. Countries: 2. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.